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ApoA-II is the second-major protein of high-density lipoproteins. C-terminal extension in human
apoA-II or point substitutions in murine apoA-II cause amyloidosis. The molecular mechanism of
apolipoprotein misfolding, from the native predominantly a-helical conformation to cross-b-sheet
in amyloid, is unknown. We used 12 sequence-based prediction algorithms to identify two ten-
residue segments in apoA-II that probably initiate b-aggregation. Previous studies of apoA-II
fragments experimentally verify this prediction. Together, experimental and bioinformatics studies
explain why the C-terminal extension in human apoA-II causes amyloidosis and why, unlike murine
apoA-II, human apoA-II normally does not cause amyloidosis despite its unusually high sequence
propensity for b-aggregation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Amyloidoses are protein misfolding diseases in which a nor-
mally soluble functional protein changes its conformation to an
intermolecular cross-b-pleated sheet and forms insoluble ﬁbrillar
deposits in vivo [1]. Apolipoproteins (apos) are lipid surface-bind-
ing proteins that are central to lipid transport and metabolism and
are overrepresented in amyloidoses [2–4]. For example, apoE4 is
an important risk factor in Alzheimer’s disease and is found in
most amyloid deposits; a-synuclein forms amyloid in Lewy bodies
in Parkinson’s disease; serum amyloid A deposits as ﬁbrils in
chronic inﬂammation; non-variant apoA-I deposits as amyloid in
atherosclerotic plaques; also, speciﬁc mutations in apoA-I, apoA-
II and other apolipoproteins can cause systemic amyloidosis in
humans ([2–4] and references therein). To prevent or block apoli-
poprotein misfolding, it is essential to understand the molecular
mechanism of this pathogenic process and its important determi-
nants, which are largely unknown. Here, we combine bioinformat-ics approaches with previous in vitro and animal model studies to
gain insight into misfolding of apolipoprotein A-II (apoA-II).
2. ApoA-II in circulation
ApoA-II (9 kDa) is the second-major protein of plasma high-
density lipoproteins (HDL, or ‘‘Good Cholesterol’’) that remove
excess cholesterol from peripheral tissues and protect against
cardiovascular disease. HDL are nanoparticles comprised of lipids
and exchangeable (water-soluble) proteins, mainly apoA-I and
apoA-II (70% and 20%, respectively). ApoA-II is an important mod-
ulator of HDL metabolism [5–7]. Most apoA-II circulates on mature
‘‘spherical’’ HDL, sHDL(A-I/A-II), that also contain apoA-I. ApoA-II is
more hydrophobic and more strongly associated with sHDL than
apoA-I or any other exchangeable apolipoprotein [5]. The amino
acid sequence of apoA-II is predicted to form three class-A amphi-
pathic a-helices that are the major structural and functional motif
in this protein family (Fig. 1A–C) [8]. Such a-helices have large
apolar faces that are optimized for lipid surface binding [9]. Two
class-A a-helices, predicted in apoA-II residues 9–30 and 51–70,
have particularly large apolar faces spanning 180 (as compared
to 120 in apoA-I) (Fig. 1A and C). These large apolar faces enable
apoA-II a-helices to insert more deeply into phospholipid mono-
layer and bind more strongly to HDL surface than other exchange-
able apolipoproteins. As a result, apoA-II does not readily
dissociate from sHDL during metabolism and, hence, is thought
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Fig. 1. Helix wheel representation of normal human apoA-I (A–C) and its amyloidogenic C-terminal extension (D). Amphipathic class-A a-helices predicted in apoA-II
residues 9–30 (A), 39–50 (B) and 51–70 (C) are shown; the C-terminal extension 78–98 does not form an amphipathic a-helix (D). Gray dotted arcs in panels A–C indicate
apolar helical faces. Residues are color-coded: apolar (black letters, ﬁlled gray circles), polar (black), acidic (red), basic (blue), Gly (gray). Circles with green edge indicate
residues located in the predicted amyloid hot spots (Fig. 2 and Supplemental Table S1).
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association with sHDL helps protect apoA-II from misfolding.
Most human apoA-II circulates on mature sHDL(A-I/A-II), which
is a major HDL species formed upon maturation and fusion of nas-
cent discoidal HDL containing either apoA-I or apoA-II, dHDL(A-I)
and dHDL(A-II); alternatively, sHDL(A-I/A-II) can form upon matu-
ration of dHDL(A-I/A-II) [10]. Nascent discoidal high-density lipo-
protein (dHDL) containing apoA-II and/or apoA-I are formed
upon efﬂux of cell cholesterol to these proteins, mediated by lipid
transporter ABCA1 ([7,10–12] and references therein). Nascent
dHDL(A-II) is a minor species that is rapidly converted into mature
sHDL(A-I/A-II) upon fusion with HDL containing apoA-I as its sole
protein (HDL(A-I)) [11,12]. In contrast to its particularly strong
association with sHDL, apoA-II dissociates relatively readily from
dHDL [13–15]; this difference is probably due to the distinct geom-
etry of the amphipathic helix–lipid interactions on discoidal and
spherical particles [6]. The dissociated apoA-II provides a potential
source of transient free apoA-II in plasma. In contrast to HDL-
bound apolipoproteins that are stabilized by high kinetic barriers
[16,17], free apoA-II in solution has reduced helical content, mar-
ginal thermodynamic stability, and forms a partially folded molten
globule [18]. This structurally labile transient species is proposed
to form the direct precursor of amyloid [19,20].
In humans, great apes and equines, apoA-II forms a dimer disul-
ﬁde-linked via the sole cysteine, Cys6, while in most other species
apoA-II lacks Cys and is monomeric. Dimer formation decelerates
apoA-II transfer among phospholipid vesicles [21], increases struc-
tural stability of apoA-II on dHDL [22], decelerates apoA-II dissoci-
ation from dHDL, and increases the activation energy of this
dissociation [13,23]. We posit that S-S linked dimer formationhelps protect human apoA-II frommisfolding by hampering its dis-
sociation from the lipid. The cross-linking studies of model
dHDL(A-II) containing dimeric human apoA-II showed that the
two molecules within the dimer form an antiparallel helical hair-
pin [24]. Such an antiparallel a-helical arrangement may provide
additional protection from apoA-II misfolding into a parallel b-
sheet, which is the major structural motif predicted and observed
in amyloid ﬁbrils formed by apolipoproteins [25–27] (discussed
below) and many other proteins [28,29].
3. Human apoA-II amyloidosis
In humans, apoA-II can cause hereditary apoA-II amyloidosis
(AApoAII), an autosomal dominant disorder that results from stop
codonmutations, stop78 to Gly, Ser, Arg or Leu, leading to a 21-res-
idue C-terminal extension ([19,20] and references therein). Full-
length mutant apoA-II deposits as ﬁbrils primarily in kidneys, caus-
ing renal damage and failure, and in other organs (heart, adrenal,
spleen, etc.). The only available treatment for AApoAII is dialysis
followed by kidney transplant [30]. It is unclear why the C-termi-
nal extension leads to amyloidosis. One explanation is that, unlike
the rest of the apoA-II molecule, this extension cannot form an
amphipathic class-A a-helix with a well-deﬁned apolar lipid-bind-
ing face (Fig. 1) and, hence, is less suited for binding to lipid surface
[19]. Benson and colleagues proposed that this reduced lipid bind-
ing afﬁnity can inﬂuence HDL metabolism and shift the population
distribution from HDL-bound to labile free apoA-II [19].
We hypothesize that the C-terminal extension may also (i)
interfere with the conformation and dynamics of free apoA-II in
solution, and (ii) increase the amyloid-forming propensity of its
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Fig. 2. Amyloidogenic proﬁles predicted for human apoA-II with the C-terminal
extension. Panel A shows the number of hits in AmylPred2 (from the total of 11)
plotted versus residue number; larger number of hits suggests improved prediction
speciﬁcity of the amyloidogenic segments [31]. Residue numbers at the top indicate
segments predicted by at least ﬁve methods (at or above the dotted line). Panel B
shows the amyloidogenic proﬁle in PASTA units [43], with higher values
corresponding to higher probability of b-strand pairing. The strongest amyloid
hot spot predicted in residues 60–70 is shown in its entirety in the insert, but is only
partially seen in panel B that zooms in on the more weakly predicted hot spots. The
b-stand orientation predicted for each hot spot is shown by arrows. Methionine
position is indicated. Panel C shows how two adjacent hot spots, 60–70 and 79–87,
can form a b-hairpin assembled in a parallel in-register intermolecular b-pleated
sheet predicted for these hot spots. Such a b-hairpin-containing assembly may
facilitate amyloid nucleation [59]. Different shades of gray show different protein
molecules. Panel D shows amphipathic class-A a-helices predicted in residues 9–30,
39–50 and 51–70.
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detailed structural and dynamic information on apoA-II becomes
available.1 To test the latter idea, we used an established concept
that protein misfolding is usually initiated by short 4- to 10-residue
segments, or amyloid ‘‘hot spots’’, with high propensity for b-aggre-
gation. To identify such amyloid hot spots in apoA-II, we analyzed its
amino acid sequence by using a combination of 12 sequence-based
prediction methods.
To this end, we used consensus software AmylPred2 [31] that
combines 11 prediction algorithms using various criteria, such as
the packing density, hydrophobicity and charge distribution, b-
sheet contiguity, correspondence to known b-sheet patterns, a-
helix to b-sheet conformational switches, dual a-helix and b-sheet
propensity, etc. [31–43]. Although individual prediction algorithms
have limited accuracy, the consensus analysis can signiﬁcantly im-
prove the selectivity and speciﬁcity in predicting hot spots for
amyloid [31]. Thus, prediction by a consensus of 5 out of 11 meth-
ods has approximately 85% speciﬁcity that increases with the
increasing number of hits in AmylPred2 [31]. In addition to Amyl-
Pred2, we used PASTA server that assesses free energy of segment
pairings in amyloid and the probable orientation of these segments
in a parallel or antiparallel b-sheet [43].
Fig. 2 and Supplemental Table S1 show the results of these
predictions for human wild type (WT) apoA-II (77 a. a.) and its
AApoAII mutant containing 21-residue C-terminal extension.
AmylPred2 reveals two major amyloid hot spots in WT apoA-II pre-
dicted by a consensus of at least 5 out of 11 methods. These include
residues 10–18, LVSQYFQTV, predicted by up to 8 methods; and
residues 60–70, LVNFLSYFVEL, predicted by up to 11 methods
(Table S1). Notably, the latter hot spot is the strongest hit for any
exchangeable apolipoprotein explored. Importantly, the C-terminal
extension contains an additional hot spot in residues 79–87,
SVQTIVFQP, predicted by nine out of 11 methods (Table S1). Each
of these hot spots is rich in large hydrophobic residues, contains
at least one aromatic residue in the middle, typically lacks basic
groups (although an acidic group is tolerated), and has other prop-
erties of amyloidogenic sequences. The rank order for the three
predicted hot spots in human apoA-II and its C-terminal extension
mutant is (60–70) > (79–87) > (10–18) (Fig. 2A).
In agreement with AmylPred2, PASTA predicts three amyloid
hot spots in similar locations and in the same rank order, and sug-
gests that the hot spot containing residues 60–70 is particularly
amyloidogenic (Fig. 2B). PASTA energy of 8.2 is predicted for
60–68 segment pairing in a parallel in-register b-sheet, which is
the largest negative (favorable) conformational energy for any
exchangeable apolipoprotein explored. Parallel b-sheet is also pre-
dicted in residues 79–87 from the C-terminal extension (PASTA en-
ergy 5.9). The N-terminal residues 7–20 are predicted more
weakly to form an antiparallel b-sheet (energy 4.5). Because the
probability of a particular conformation increases exponentially
with its negative energy, these energy values predict with high
probability that WT and mutant apoA-II form parallel in-register
b-sheet in amyloid.
Notably, AmylPred2 and PASTA consistently show that apoA-II
sequence has the strongest amyloid-forming propensity of all hu-
man exchangeable apolipoproteins, including apoE that is found
in most amyloid deposits, as well as a-synuclein and serum amy-
loid A that form amyloid in Parkinson’s disease and inﬂammation,
respectively. This is not surprising, since amyloid-forming propen-
sity correlates with the protein hydrophobicity, and apoA-II is most1 X-ray crystal structures of full-length human apoA-II and other proteins
previously published by H.M. Murphy have been discredited and should be
withdrawn from the journals and the Protein Data Bank. For details see [58], http://
main.uab.edu/Sites/reporter/articles/71570/ and http://classic.the-scientist.com/blog/
display/56226/.hydrophobic of all exchangeable apolipoproteins. Remarkably, the
predicted amyloid-forming propensity of apoA-II is comparable to
that of Alzheimer’s Ab peptide (prediction results not shown). Nev-
ertheless, normal human apoA-II does not form amyloid in vivo. To
explain this paradoxical ﬁnding, we note that the two amyloid hot
spots predicted in residues 10–18 and 60–70 of the wild type (WT)
human apoA-II are located inside the class-A a-helices, 9–30 and
51–70 (Figs. 1A–C and 2). We propose that strong binding of these
a-helices to sHDL surface protects these two hot spots from initi-
ating protein misfolding. Additional protection is probably pro-
vided by the disulﬁde link in human apoA-II dimer, which
848 O. Gursky / FEBS Letters 588 (2014) 845–850decelerates protein’s dissociation from the lipid surface [21,22],
including dHDL surface [13–15,23].
In conclusion, amino acid sequence analysis of apoA-II suggests
a dual effect of the 21-residue C-terminal extension explaining
why it causes amyloidosis in humans. First, this extension cannot
form an amphipathic a-helix with a well-deﬁned apolar helical
face that is necessary for optimal lipid surface binding (Fig. 1). Sec-
ond, the extension contributes an additional amyloid hot spot that
increases protein’s propensity to misfold from an antiparallel
highly helical conformation to a parallel in-register b-sheet
(Fig. 2C). This additional hot spot in residues 79–87 can act in
synergy with the strongest hot spot predicted in apoA-II residues
60–70, which also has high propensity to form a parallel in-register
b-sheet (Fig. 2B). We speculate that these two adjacent hot spots
can form a b-hairpin arranged in a parallel in-register b-sheet that
nucleates amyloid (Fig. 2C). As a result, the lipid-binding afﬁnity of
apoA-II is expected to decrease while its intrinsic amyloid-forming
propensity to increase upon the stop codon mutations. Both effects
are probably more pronounced in the mutant/mutant apoA-II
homodimer as compared to WT/mutant heterodimer. This helps
explain why only the mutant protein is found in patient-derived
AApoAII deposits, even though both homo- and heterodimers con-
taining mutant and WT apoA-II are found in circulation [19].0 10 20 30 40 50 60 70 80
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Fig. 3. Amyloidogenic proﬁles predicted for normal murine apoA-II. Panel A shows
the number of hits in AmylPred2 plotted versus residue number. Segments
predicted by at least ﬁve methods (at or above the dotted line) are shown at the
top by residue numbers. Green bars and boxed residue numbers at the bottom
indicate protein fragments that can readily form amyloid ﬁbrils in vitro [53,54].
Panel B shows the amyloidogenic proﬁle in PASTA units. The strongest predicted
hot spot encompassing residues 60–70 is shown in its entirety in the insert, but is
only partially seen in panel B that zooms in on the more weakly predicted N-
terminal hot spot. Arrow pairs show the predicted b-stand orientation. Met
positions are indicated. Green bars and residue numbers at the bottom indicate
single amino acid substitutions that differentiate various types of murine apoA-II:
normal (Pro5, Asp20, Met26. Ala38), type A (Pro5, Asn20, Met26, Ala38), type B
(Pro5, Glu20, Val26, Val38), and type C (Gln5, Glu20, Val26, Ala38); type C readily
forms amyloid in mice [46].4. Murine apoA-II amyloidosis
In contrast to human AApoAII, which is a rare hereditary disor-
der, murine AApoAII is commonly associated with aging in many
mouse strains and can be accelerated by mutations but does not
require them [44,45]. The disease is especially severe in the
senesce-accelerated mice where full-length mature apoA-II or
pro-apoA-II containing a ﬁve-residue propeptide, ALVKR, deposits
as ﬁbrils in vital organs (liver, kidneys, heart, muscle, vessel wall,
etc.) Pro-apoA-II was proposed to be particularly amyloidogenic
and perhaps nucleate AApoAII amyloid [45]. Several types of
murine apoA-II have been reported, which differ in residues at
positions 5, 20, 26 and 38, and in their amyloid-forming propensity
in vivo. Of those, type C apoA-II that contains Gln5 is particularly
amyloidogenic [46]. Remarkably, apoA-II ﬁbrils can be transmitted
through various mechanisms (e.g. via an injection or with food
[47–49]) and cause murine AApoAII in senescence-resistant
strains, probably by nucleating the misfolded conformation in
the amyloid-resistant type of apoA-II ([44] and references therein).
We speculate that high amyloidogenic propensity of the apoA-II
sequence augments such a prion-like infectious transmission of
AApoAII in mice.
The molecular mechanism of murine apoA-II misfolding and the
role of the pro-peptide and the substitutions in residues 5, 20, 26
and 38 in this process are unknown. Additional factors that can
inﬂuence AApoAII are also not well understood. Higuchi’s team
showed that such factors include dietary lipids that can impor-
tantly inﬂuence not only lipoprotein metabolism but also the
severity of murine AApoAII [50]. For example, increasing the de-
gree of fatty acid unsaturation in the diet enhances murine AA-
poAII, an effect that may be due, at least in part, to high
susceptibility of the unsaturated fatty acids to oxidation [51]. In
fact, lipid peroxidation is expected to promote Met oxidation in
apolipoproteins, and thereby reduce the structural stability of
apoA-II in solution and on HDL [52], which is expected to augment
the misfolding.
To gain better insight into the misfolding of murine apoA-II, we
analyzed its amino acid sequence by using AmylPred2 and PASTA.
The results show that full-length murine apoA-II is predicted to
have two major amyloid hot spots in the N- and C-terminal
locations (Fig. 3) similar to those predicted for human apoA-II.Importantly, this prediction has been veriﬁed experimentally: Hig-
uchi’s team showed that synthetic peptides containing residue
fragments 6–16 and 48–65 of murine apoA-II, which overlap the
predicted amyloid hot spots (Fig. 3A), readily form ﬁbrils in vitro
and are essential for amyloid nucleation [53,54]. Further, in murine
apoA-II, the C-terminal amyloid hot spot is predicted strongly to
form parallel in-register b-sheet (PASTA energy 6.6, weaker than
8.2 in human AApoAII), while the antiparallel b-sheet in the
N-terminal hot spot is predicted very weakly (PASTA energy below
the threshold of 4, weaker than 4.5 in human apoA-II) (Figs. 2B
and 3B).
Notably, the four amino acids in positions 5, 20, 26, and 38,
which differentiate amyloid-prone (type C) from amyloid-resistant
mice (types A and B), are located outside the amyloid hot spots
(Fig. 3B). Replacements of these amino acid is not predicted to sig-
niﬁcantly inﬂuence the amyloidogenic proﬁle of apoA-II (results
not shown). Similarly, the ﬁve-residue basic pro-peptide, ALVKR,
is not predicted to increase the amyloidogenic propensity of
apoA-II sequence. Consequently, the increased amyloid formation
by type C apoA-II and by pro-apoA-II observed in vivo must result
from other, still unknown, factors. We speculate that these factors
possibly include the effects of the amino acid substitutions and the
pro-peptide on the protein–lipid interactions and on the conforma-
tion and dynamics of free apolipoprotein, as proposed in our
current structure-based studies of apoA-I [55].
O. Gursky / FEBS Letters 588 (2014) 845–850 849In sum, AmylPred 2 and PASTA consistently predict two hot
spots in murine apoA-II, which have been veriﬁed experimentally
in peptide fragment studies [53,54]. The locations of these hot
spots are similar but their predicted amyloid-forming propensities
are slightly weaker as compared to their human counterparts
(Figs. 2B and 3B). Nevertheless, WT murine apoA-II commonly
forms amyloid in vivo, while WT human apoA-II does not.
To explain this ﬁnding, we propose that dimerization of human
but not murine apoA-II via the disfulﬁde link confers extra protec-
tion frommisfolding into amyloid. Furthermore, lower Met content
in human as compared to murine apoA-II may also play a role. Apo-
lipoprotein methionines can readily oxidize in vivo and in vitro and
thereby inﬂuence protein misfolding in amyloid [56]. Speciﬁcally,
the replacement of the apolar Met with polar Met sulfoxide in
the apolar helical face can destabilize the free protein and reduce
its afﬁnity for lipid, as reported for human apoA-I and apoA-II
[52,57]. Human apoA-II has a single M26 at the edge of the apolar
helical face (Fig. 1A) outside the amyloid hot spots. Murine apoA-II
contains three Met located in the middle (M7, M68) or at the edge
(M17) of the apolar helical faces, inside or adjacent to the amyloid
hot spots (Fig. 3B). Oxidation of these methionines, which reduces
protein’s afﬁnity for lipid, is expected to augment murine AApoAII.
Finally, profound differences in the lipoprotein metabolism,
including factors such as dietary lipids, may importantly inﬂuence
the development of AApoAII in mice and men [50,51].
5. Summary
Amino acid sequence analysis of human and murine apoA-II
predicts two 10-residue segments with high propensity to initi-
ate protein misfolding (Figs. 2 and 3), which is higher than in
any other exchangeable apolipoprotein explored. This prediction
has been veriﬁed experimentally for murine apoA-II whose frag-
ments encompassing the predicted segments readily form amyloid
in vitro [53,54]. Despite its unusually high sequence propensity,
normal apoA-II does not form amyloid in humans. We propose that
normal apoA-II is protected from misfolding by its strong interac-
tions with HDL surface, which is further enhanced upon dimeriza-
tion of human apoA-II via Cys6-Cys6 disulﬁde [13–15,21–23].
Amyloidogenic mutations in human apoA-II produce C-terminal
extension that has a dual effect. First, the extension contains an
additional amyloid hot spot that is predicted to act in synergy with
the major hot spot and form a parallel in-register intermolecular b-
sheet in amyloid (Fig. 2). Second, the extension cannot form class-A
amphipathic a-helix (Fig. 1) and hence, is expected to reduce
apoA-II afﬁnity for lipid surface. In mice, unlike humans, apoA-II
forms amyloid without such an extension. Perhaps this difference
can result from lower protection of murine apoA-II monomer as
compared to human apoA-II dimer by the lipid interactions, as well
as from other factors such as the differences in HDL composition
and dietary lipids [50,51]. Identifying and targeting such factors
can ultimately help combat apolipoprotein amyloidoses.
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